companion diagnostics
The current and future state of companion diagnostics
... with companion diagnostics before they can be prescribed, has moved the entire companion diagnostic field ...corresponding diagnostics, the field has expanded to include multiple therapeutic ...
12
Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers : companion diagnostics for personalized medicine
... Here, we employed a bioinformatics approach to identify novel molecular determinants to predict tumor progression and overall survival in gastric cancer patients. In particular, we directly assessed whether ...
13
Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta- analyses
... named companion diagnostics and are defined by the US Food and Drug Administration (FDA) as in vitro diagnostic devices that provide information that is essential for the safe and effective use of a ...
12
Mitochondrial markers predict survival and progression in non small cell lung cancer (NSCLC) patients : use as companion diagnostics
... new companion diagnostics to assist clinicians in more accurately predicting clinical outcomes in lung cancer patients, driving more personalized cancer ...
14
Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer : companion diagnostics for cancer therapy
... mitochondrial-based companion diagnostics for personalized cancer ...mitochondrial-based diagnostics would be used to separate ovarian cancer patients into higher- risk and lower-risk ...
16
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives
... Growing knowledge of the molecular underpinnings comprising the etiology of cancer has driven the field of personalized or “precision” medicine to identify specific tumor characteristics and exploit these features by ...
10
Lyme disease: the promise of Big Data, companion diagnostics and precision medicine
... Improved companion diagnostic tests for Lyme disease need to be implemented, and novel treatment approaches are urgently needed to combat the ...registries, companion diagnostics and precision ...
5
Mitochondrial markers predict recurrence, metastasis and Tamoxifen resistance in breast cancer patients : early detection of treatment failure with companion diagnostics
... Several classes of FDA-approved antibiotics safely inhibit either mitochondrial biogenesis or OXPHOS as off-target “side-effects”. These include the tetracyclines (doxycycline), the erythromycins (azithromycin), ...
17
Optimal Contract Design for Co-development of Companion Diagnostics
... and diagnostics industries operate along very di ff erent paths with “di ff erent development timelines, product lifecycles, return on investment, customers and regulations” ...of companion diag- nostics ...
147
Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials
... cancer diagnostics market and the emergent attention of regulatory agencies worldwide, who are beginning to offer more struc- tured platforms and guidance for this ...using companion diagnostics and ...
9
Targeted treatment of mutated <em>EGFR</em>-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
... There is a growing trend toward the extensive molecular characterization of tumors to select the most appropriate therapy. The benefits of EGFR TKI treatment can be maximized if used with clinically validated and ...
7
Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide
... Abstract: Among the gynecological malignancies, ovarian cancer is the leading cause of mortality in developed countries. Treatment of ovarian cancer is based on surgery integrated with chemotherapy. Platinum-based drugs ...
12
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
... opment, companion diagnostics, patient population, principal investigator/site selection and management, and monitoring strategies are key areas on which to focus to establish a foundation for the ...
10
Is the Fatty Acids Profile in Blood a Good Predictor of Liver Changes? Correlation of Fatty Acids Profile with Fatty Acids Content in the Liver
... The next study conducted by our research team was based on fatty acid erythrocytes membrane profiles and showed that steatosis reduction is related to a significant reduction in stearic [r] ...
9
Overall Survival and Adjuvant Therapy in Women with Ovarian Carcinosarcoma: A Single-Institution Experience
... A similarly sized cohort treated at Memorial Sloan-Kettering Cancer Center found that treatment with carboplatin / taxol may be a suitable first-line chemotherapy regimen with a median s[r] ...
8
Evaluation of Hepatic Steatosis in Rodents by Time-Domain Nuclear Magnetic Resonance
... Body Composition Analyzer is Not Accurate for Determining Hepatic Steatosis in Mice Fed HFD Mice fed HFD for 4 weeks showed higher body weight compared to the control group receiving cho[r] ...
9
Diagnostic Approach to Traumatic Axonal Injury of the Spinothalamic Tract in Individual Patients with Mild Traumatic Brain Injury
... Abstract: Objectives: We investigated an approach for the diagnosis of traumatic axonal injury (TAI) of the spinothalamic tract (STT) that was based on di ff usion tensor tractography (D[r] ...
7
A Concise Companion to History
... Wong makes a refreshing contribution to the Companion. It seems to take us beyond ideological impasses, opening up a space in which historians can acknowledge the richness and complexity of the local while still ...
6
Consolato M. Sergi 1,2
... 22. Rodriguez-Gonzalez, M.; Perez-Reviriego, A.A.; Castellano-Martinez, A.; Lubian-Lopez, S.; Benavente-Fernandez, I. Left Ventricular Dysfunction and Plasmatic NT-proBNP Are Associated with Adverse Evolution in ...
5
Protein Carbonyl Content Is a Predictive Biomarker of Eccentric Left Ventricular Hypertrophy in Hemodialysis Patients
... CRP: C-reactive protein; IDWG: interdialytic weight gain; NG: normal left ventricle geometry; CR: concentric remodeling; cLVH: concentric left ventricular hypertrophy; eLVH: eccentric [r] ...
13